ABOUT this BLOG and How to use it

WELCOME to Stu's Views and MS News e-Newsletter Ô

Key-Note: Our live MS educational seminars average approx 65 people per educational program and SINCE our first program in February 2010, we have hosted more than 118 educational programs. Most locations are in Florida and we have now added educational events in Georgia, Alabama and the Carolinas.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries.

Visit MS Views and News.org

Be Empowered with MS News and Information

Scroll to view All the resources found on the left side of this blog. Need to find information, use our 'search by topic' tool.


~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Thursday, January 24, 2013

Biogen Sees Positive Results From Study of Potential Multiple Sclerosis Treatment

By Dow Jones Business News,  January 24, 2013,


By Saabira Chaudhuri
Biogen Idec ( BIIB ) said data from a late-stage trial of its potential multiple-sclerosis treatment were positive.
The biopharmaceutical company said results support peginterferon beta-1a as a potential treatment dosed every two weeks or every four weeks for relapsing-remitting multiple sclerosis.
"If approved, peginterferon beta-1a will represent an innovation that offers patients a less frequent dosing schedule of no more than 26 doses annually, as well as a significant reduction in relapses and disability progression," said Gilmore O'Neill, vice president of global neurology late stage clinical development at Biogen.
Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that peginterferon beta-1a also met the secondary endpoints. It noted that with both dose regimens studied the risk- benefit profile of peginterferon beta-1a appears to be favorable.
The Phase 3 study included more than 1,500 patients with RRMS and was designed to evaluate the efficacy, safety and tolerability of peginterferon beta-1a compared to placebo at one year.
Earlier this month, Biogen said its Phase 3 clinical trial for an ALS treatment didn't meet its primary goals, causing it to discontinue development of the drug for the disease.
And in October, Biogen reported its third-quarter earnings rose 13% as the biopharmaceutical company saw growth of its biggest drug, multiple-sclerosis treatment Avonex, and received a boost from a gain tied to Benlysta.
  (END) Dow Jones Newswires
  01-24-130808ET
  Copyright (c) 2013 Dow Jones & Company, Inc.

SOURCE : NASDAQ
..


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.

1 comment:

wayne fenton said...

for rrms only how many drugs for rrms only not one for spms or ppms , you make sure you show how much you make in increased sales off the backs of the patients 13% increase , rrms must good for sales but what damage is it doing to the recipient, there have been no medications that work for any other diseases ALS that work. why have you not produced anything for spms or ppms you dont know how , not enough money in it , too difficult , or is it you only want to take the easier more profitable route.